Motilal Oswal has issued a buy rating on Global Health (Medanta) with a target price of ₹1,375 in its research report dated February 05, 2026. According to reports from Moneycontrol, the brokerage values the healthcare company at 27x 12-month forward EV/EBITDA to arrive at this target price.
Global Health (Medanta) exhibited higher-than-expected revenue for the quarter, as reported by Moneycontrol. However, the company's EBITDA and PAT were lower than estimated, with misses of 9% and 18% respectively. The underperformance was largely attributed to higher operational expenses related to the Noida scale-up.
The company continued to demonstrate healthy year-on-year growth in both inpatient (IPD) and outpatient (OPD) services for the quarter, according to Moneycontrol reports. The share of IPD in cash, insurance, and schemes remained largely stable both year-on-year and quarter-on-quarter, indicating consistent revenue diversification across payment methods.
Motilal Oswal has cut its estimates by 12%/5%/3% for FY26/FY27/FY28 respectively, as reported by Moneycontrol. The revision factors in increased losses related to Noida operations and higher operational costs for matured hospitals. These adjustments reflect the company's current operational challenges and expansion costs.
